user avatar
Jeff Ryckman
@jryckman3
Medical Physicist ➡️ Rad Onc | Chasing LR-PFS 🎯, QoL ⚖️ & reproducibility 📊 | Building @RadOncReview + #RadOncCalc | Opinions my own, not medical advice
CancerRetreatment.org
Joined October 2009
3,519
Following
4,798
Followers
1
Subscription
Posts
  • Pinned
    user avatar
    Jeff Ryckman
    @jryckman3
    Jun 2
    At some point, we have to ask whether continuing to build large phase III trials on a local therapy backbone with ~40 to 60% failure is the best use of resources. Positive PFS is not surprising when LC is the weak link. We can do better in 2026. #ASCO26 #OncTwitter
    user avatar
    Rachna Shroff, MD, MS, FASCO
    @rachnatshroff
    Jun 1
    Sticking with 80’s rock themes…”take me down to the EMERALD city!!” - EMERALD-3 hits the 🎯 for PFS - STRIDE + Lenva + TACE vs TACE alone, 13 v. 9.8 mths, OS pending but trending! Congrats @GABOUALFA and colleagues! @ASCO @UAZCancer
    4.4K
  • user avatar
    Jeff Ryckman
    @jryckman3
    Nov 23, 2024
    Replying to @VPrasadMDMPH
    It’s ironic that if Trump had supported lockdowns, school closures, & vaccine mandates, the opposition might have taken the opposite stance. In such a scenario, schools might have remained open, & C19 vaccines might not have been mandated. This highlights the absurdity of our
    25K
  • user avatar
    Jeff Ryckman
    @jryckman3
    Dec 22, 2024
    🎉 Excited to share our latest work: RadOncCalc – A Mobile-Friendly Tool to Enhance Radiation Oncology Practice 📱⚛️ How does RadOncCalc help radiation oncologists save time and enhance patient care? Let’s break it down in this Tweetorial! practicalradonc.org/article/S1879-… 🧵👇
    37K
  • user avatar
    Jeff Ryckman
    @jryckman3
    Jul 26, 2022
    Is there a role for Local Tx of the Primary Tumor for Patients with Metastatic Cancer? 🚫Many studies demonstrate no benefit. 📌We performed a MetaAnalysis to evaluate the average effect of Local Tx across various tumors. A thread🧵#AMSM #PRIMETX redjournal.org/article/S0360-… 1/25
  • user avatar
    Jeff Ryckman
    @jryckman3
    Apr 15, 2023
    Wow, this made the @nytimes! 🤯 #radonc #fixpriorauth nytimes.com/interactive/20…
    user avatar
    Jeff Ryckman
    @jryckman3
    Mar 27, 2023
    Wow, I can't get over the accuracy of insurance rebuttals using Chat-GPT! What used to take me around a half hour to write now takes one minute. Such a huge time-saver, and with some guidance, even the Bibliographies can sometimes check out! #radonc #PCSM
    49K
  • user avatar
    Jeff Ryckman
    @jryckman3
    Jun 2, 2025
    Thrilled to share that I’ve been promoted to Associate Professor! Endlessly grateful to those who’ve supported me along the way, too many to tag, and more generous than I could ever deserve. I’m looking forward to continuing to grow, learn, and give back in whatever way I can.
    6.9K
  • user avatar
    Jeff Ryckman
    @jryckman3
    Apr 10, 2023
    This three-pager is a must-read by every oncologist. Chris Booth is one of my heroes #timetoxicity “Thus, intensive treatments associated with more time toxicity are not incorrect choices themselves, and decisions for patients should be individualized. The most important first
    user avatar
    Anirban Maitra
    @Aiims1742
    Apr 10, 2023
    Replying to @statnews @matthewherper and @Charlotte_Huff
    Here’s the #OpenAccess commentary on the time toxicity of cancer treatment by @guptaarjun90 and colleagues. ascopubs.org/doi/10.1200/JC…
    104K
  • user avatar
    Jeff Ryckman
    @jryckman3
    Nov 18, 2023
    Radiotherapy sentiment in @nytimes is eye-opening. Since 2009, over half of articles show negative bias towards RT, while only 1/4 are positive. Despite major advancements in tech like MR-Linac, adaptive RT, & heavy ions, media celebration is scarce. thegreenjournal.com/article/S0167-… 1/7
    138K
  • user avatar
    Jeff Ryckman
    @jryckman3
    Oct 18, 2022
    Constraint data is confusing.😵‍💫 Here is the final product of nearly a decade of work, 2,500+ metrics (+citations!) and counting, just in time for #ASTRO22 @ASTRO_org 🦾🎯 HT @culbert_md for creating this fantastic GUI 💫 We hope you find this helpful in your practice! #RadOnc
    00:00
    user avatar
    radoncreview_org
    @radoncreview
    Oct 18, 2022
    🗣️We are SO excited to announce #RadOncCalc is now available on the web! RadOncCalc.RadOncReview.org Includes: 📌Per-OAR contouring instructions with links to @eContourRadOnc cases. 📌Data for Brachytherapy, Re-RT, & all Fx schemes. 📌FREE access! 📌2,500 metrics & counting #RadOnc
  • user avatar
    Jeff Ryckman
    @jryckman3
    Mar 27, 2023
    Wow, I can't get over the accuracy of insurance rebuttals using Chat-GPT! What used to take me around a half hour to write now takes one minute. Such a huge time-saver, and with some guidance, even the Bibliographies can sometimes check out! #radonc #PCSM
    67K
  • user avatar
    Jeff Ryckman
    @jryckman3
    May 2, 2022
    I put together a few high-yield slides for #RadOnc oral boards RT-friendly regimens for HL and NHL. 📌 For HL, there is a focus on GHSG staging for a simplified decision tree. 📌 Goal: Not comprehensive. Comments and feedback are welcomed! Enjoy 😃 bit.ly/RadOncHemeOral…
  • user avatar
    Jeff Ryckman
    @jryckman3
    Aug 22, 2022
    1 year LC 99% with 🫁 SABR for metastatic #sarcoma patients "unsuitable for surgery"#radonc 📌 30/1, 60/3, and 48/4 for peripheral ≤ 1 cm, 1.1-2.0 cm, and > 2.0 cm, respectively. 📌 60/8 for central. So, what RCT made surgery SoC? 🧐 Fantastic work!🥇 pubmed.ncbi.nlm.nih.gov/35987453/
  • user avatar
    Jeff Ryckman
    @jryckman3
    Apr 27, 2021
    After over a year of work, my non-canonical paper concerning the TIMING of neoadj RT for pancreatic ca is out! Includes A021501 commentary and thoughtful review of current paradigm. HT @whallradonc @mbaineunmcedu1 et al for their support! #radonc #PancSM sciencedirect.com/science/articl…
  • user avatar
    Jeff Ryckman
    @jryckman3
    Dec 29, 2021
    Slowly getting around to building in #reirradiation constraints. 📌 Conventional re-RT for the cord is up! 📌 Re-RT filter (for all OARs) coming soon! 🚧🏗️ Please let us know if you have any feedback. Your critique is vital to the success of this project! #RadOncCalc #radonc